Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 256 AL 270

Clinical data in early intervention

Kasper S.

Int Psychogeriatr. 2012 Aug;24 Suppl 1:S41-5. doi: 10.1017/S1041610212000555.

Walking the cognitive "minefield" between high and low blood pressure

Kennelly S, Collins O.

J Alzheimers Dis. 2012;32(3):609-21. doi: 10.3233/JAD-2012-120748.

Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases

Osmonov D, Özcan KS, Erdinler I, Altay S, Turkkan C, Yildirim E, Gurkan K.

Am J Alzheimers Dis Other Demen. 2012 Aug;27(5):311-4. doi: 10.1177/1533317512452040.

Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention

Valenzuela M, Esler M, Ritchie K, Brodaty H.

Transl Psychiatry. 2012 Apr 24;2(4):e107. doi: 10.1038/tp.2012.28.

Alzheimer's disease in a dish: promises and challenges of human stem cell models

Young JE, Goldstein LS.

Hum Mol Genet. 2012 Oct 15;21(R1):R82-9. doi: 10.1093/hmg/dds319. Epub 2012 Aug 2.

Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial

Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group.

Lancet Neurol. 2012 Oct;11(10):851-9. doi: 10.1016/S1474-4422(12)70206-5. Epub 2012 Sep 6.

Relapse risk after discontinuation of risperidone in Alzheimer's disease

Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B.

N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058.

Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress

Quintanilla RA, Orellana JA, von Bernhardi R.

Arch Med Res. 2012 Nov;43(8):632-44. doi: 10.1016/j.arcmed.2012.10.016. Epub 2012 Nov 8.

Vitamin E for Alzheimer's dementia and mild cognitive impairment

Farina N, Isaac MG, Clark AR, Rusted J, Tabet N.

Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD002854. doi: 10.1002/14651858.CD002854.pub3.

Phosphodiesterases as therapeutic targets for Alzheimer's disease

García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R.

ACS Chem Neurosci. 2012 Nov 21;3(11):832-44. doi: 10.1021/cn3000907. Epub 2012 Oct 1.

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Smith B, Medda F, Gokhale V, Dunckley T, Hulme C.

ACS Chem Neurosci. 2012 Nov 21;3(11):857-72. doi: 10.1021/cn300094k. Epub 2012 Aug 28.

Alzheimer's dementia: a brief review

Bassil N, Mollaei C.

J Med Liban. 2012 Oct-Dec;60(4):192-9.

Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics

Bakulski KM, Rozek LS, Dolinoy DC, Paulson HL, Hu H.

Curr Alzheimer Res. 2012 Jun;9(5):563-73. doi: 10.2174/156720512800617991.

[Review in geriatric medicine 2011]

Rochat S, Doser N, Eyer S, Jabri A, Rubli E, Büla C.

Rev Med Suisse. 2012 Jan 11;8(323):23-7.

Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease

Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS.

J Neural Transm (Vienna). 2012 Jul;119(7):843-50. doi: 10.1007/s00702-012-0772-4. Epub 2012 Feb 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias